Female Sexual Dysfunction Treatment Market Size, Share and Global Trend By Type (Arousal Disorder, Penetration Disorder, Female Orgasmic Disorder), By Therapy (Estrogen Therapy, Androgen Therapy, Others), By Age (25 Years, 25-40 Years, Above 40 Years) and Geography Forecast Till 2030

Sexual dysfunction refers to a problem during any phase of the sexual cycle that intercepts individual and couple to meet sexual satisfaction. Sexual dysfunction is seen in both male and females, but according to studies, it is found that female is more prone to sexual dysfunction than men. The rise in alcohol intake, drug abuse, menopause, use of anti-depressants, stress and anxiety, relationship and marital problems, depression, and many others are some of the causes of sexual dysfunction.

Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) of bremelanotide, a first-in-class melanocortin-4 receptor agonist designed by AMAG Pharmaceuticals for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

To gain extensive insights into the market, Request for Customization

The global female sexual dysfunction treatment market is expected to grow rapidly during the forecast period, owing to the increasing incidences of sexual dysfunction among women. The rise in the adoption of an unhealthy lifestyle, an increase in consumption of alcohol, and a rise in awareness of the treatment may also lead to an increase in demand of the female dysfunction treatment market. New product introductions in the market, are expected to drive the demand and propel the growth of the global female sexual dysfunction treatment market from 2019-2026. 

The factor inhibiting the growth of female sexual dysfunction market is lack of awareness of treatment in developing countries, lack of standardization in the treatment of sexual dysfunction and social barriers for treatment.

Key Players Covered

Some of the key players present in the global Female Sexual Dysfunction Treatment market are Apricus Biosciences, Inc., GlaxoSmithKline, plc., Pfizer, Inc., AMAG Pharmaceuticals, Merck & Co., Inc., Cipla Inc., and others.

SEGMENTATION

At present, the age group of 40 and above accounts for the highest market share in the treatment of the global female sexual dysfunction treatment market. This is expected to grow at a significant CAGR during the forecast period due to the adoption of an unhealthy lifestyle and frequent hormonal imbalance leading to sexual dysfunction.

Key Insights

• Prevalence of female sexual dysfunction
• Regulatory Scenario (Key Countries)
• Pipeline Analysis (By Key Regions) 2019
• Key Mergers and Acquisitions

Regional Analysis

The global female sexual dysfunction treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for female sexual dysfunction treatment at present and they are expected to account for a large proportion of the market in the forecast period as well owing to increasing aging population, unhealthy lifestyle, rise in consumption of alcohol, and the increase in awareness about sexual dysfunction treatment. Asia Pacific is expected to register comparatively higher CAGR from 2019-2026 due to government initiatives towards the awareness of the treatment for female sexual dysfunction and increasing health care expenditure.

Key Industry Developments

• In June 2018, AMAG Pharmaceuticals, Inc., received approval from U.S. Food and Drug Administration (FDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
• In June 2018, Pivot Pharmaceuticals Inc. announced the filing of the Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and Clinical Trial Application (CTA) with Health Canada to begin human clinical trials of PVT-005 for the treatment of Female Hypoactive Sexual Desire Disorder (HSDD).
• In August 2015, Sprout Pharmaceuticals, Inc., received FDA approval for the Addyi. Addyi is the first and only FDA-approved treatment for acquired, generalized hypoactive (low) sexual desire disorder—HSDD—in women who have not gone through menopause.